aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

LIFE 12.17.2024

Full Press ReleaseSEC FilingsOur LIFE Tweets

About Gravity Analytica

Recent News

  • 01.16.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.07.2025 - Dev Prasad
  • 01.07.2025 - Prakhar Agrawal

Recent Filings

  • 01.10.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.08.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
  • 12.23.2024 - 424B5 Prospectus [Rule 424(b)(5)]

SAN DIEGO,Dec. 17, 2024(GLOBE NEWSWIRE) --aTyr Pharma, Inc.(Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced thatSanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the 43rdAnnualJ.P. Morgan Healthcare Conference, which is scheduled to take placeJanuary 13– 16, 2025, inSan Francisco, CA.

Details of the presentation appear below:

Conference: 43rdAnnualJ.P. Morgan Healthcare ConferenceDate:Thursday, January 16, 2025Time:8:15am PSTLocation:San Francisco, CAFormat: Corporate Presentation

In addition to the presentation, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conference. A webcast of the presentation will be available on the Investor’s section of the company’s website atwww.atyrpharma.com. Following the event, a replay of the presentation will be available on the aTyr website for at least 30 days. For more information, contactinvestorrelations@atyrpharma.com.

About aTyr

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visitwww.atyrpharma.com.

Contact:Ashlee DunstonDirector, Investor Relations and Public Affairsadunston@atyrpharma.com

Primary Logo

Source: aTyr Pharma, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com